Anixa Biosciences Inc (ANIX) NPV
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on oncology and infectious disease. The Company is developing chimeric endocrine receptor T-cell technology, a chimeric antigen receptor T-cell (CAR-T) technology focused on treating ovarian cancer, and anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. It is also developing vaccine against triple negative breast cancer (TNBC), the lethal form of breast cancer, and a vaccine against ovarian cancer. Its subsidiary Certainty Therapeutics, Inc. (Certainty), is developing immuno-therapy drugs against cancer.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.